Long-term incidence trends of HPV-related cancers, and cases preventable by HPV vaccination: A registry-based study in Norway

BMJ Open

Volumn 8, Issue 2, 2018, Pages

  Hansen, Bo T ^a   Campbell, Suzanne ^a   Nygård, Mari ^a  

^a CANCER REGISTRY OF NORWAY   (Norway)

Author keywords

epidemiology; preventive medicine; public health

Indexed keywords

WART VIRUS VACCINE;

ANUS CARCINOMA; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CANCER REGISTRY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; MALE; NONHUMAN; NORWAY; OBSERVATIONAL STUDY; OROPHARYNX SQUAMOUS CELL CARCINOMA; PENIS CARCINOMA; PREVALENCE; UTERINE CERVIX ADENOCARCINOMA; UTERINE CERVIX CARCINOMA; VAGINA CARCINOMA; VULVA CARCINOMA; WART VIRUS; ADULT; AGED; CLASSIFICATION; INCIDENCE; MIDDLE AGED; NEOPLASM; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; REGISTER; SQUAMOUS CELL CARCINOMA; STATISTICAL MODEL; VIROLOGY; VIRUS INFECTION;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; INCIDENCE; LINEAR MODELS; MALE; MIDDLE AGED; NEOPLASMS; NORWAY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; REGISTRIES; TUMOR VIRUS INFECTIONS;

EID: 85050730624     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2017-019005     Document Type: Article

References (50)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
2. papillomaviruses IHIARC Monogr Eval Carcinog Risks Hum 2012;100B:255-313.
3. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030-44.
4. Bernard HU, Burk RD, Chen Z, et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010;401:70-9.
5. Ma Y, Madupu R, Karaoz U, et al. Human papillomavirus community in healthy persons, defined by metagenomics analysis of human microbiome project shotgun sequencing data sets. J Virol 2014;88:4786-97.
6. Egawa N, Egawa K, Griffin H, et al. Human Papillomaviruses; Epithelial Tropisms, and the Development of Neoplasia. Viruses 2015;7:3863-90.
7. Alemany L, Saunier M, Alvarado-Cabrero I, et al. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer 2015;136:98-107.
8. Alemany L, Saunier M, Tinoco L, et al. Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. Eur J Cancer 2014;50:2846-54.
9. Alemany L, Cubilla A, Halec G, et al. Role of Human Papillomavirus in Penile Carcinomas Worldwide. Eur Urol 2016;69:953-61.
10. de Sanjosé S, Alemany L, Ordi J, et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer 2013;49:3450-61.
11. Ndiaye C, Mena M, Alemany L, et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol 2014;15:1319-31.
12. Fossum GH, Lie AK, Jebsen P, et al. Human papillomavirus in oropharyngeal squamous cell carcinoma in South-Eastern Norway: prevalence, genotype, and survival. Eur Arch Otorhinolaryngol 2017;274:4003-10.
13. Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011;128:927-35.
14. Serrano B, de Sanjosé S, Tous S, et al. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Eur J Cancer 2015;51:1732-41.
15. Muñoz N, Manalastas R, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009;373:1949-57.
16. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:89-99.
17. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015;372:711-23.
18. Garland SM, Kjaer SK, Muñoz N, et al. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis 2016;63:519-27.
19. Sasieni PD, Cuzick J, Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. Br J Cancer 1996;73:1001-5.
20. Lönnberg S, Hansen BT, Haldorsen T, et al. Cervical cancer prevented by screening: Long-term incidence trends by morphology in Norway. Int J Cancer 2015;137:1758-64.
21. Vaccarella S, Franceschi S, Engholm G, et al. 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. Br J Cancer 2014;111:965-9.
22. Bray F, Carstensen B, Møller H, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev 2005;14:2191-9.
23. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006;24:S11-S25.
24. Baldur-Felskov B, Hannibal CG, Munk C, et al. Increased incidence of penile cancer and high-grade penile intraepithelial neoplasia in Denmark 1978-2008: a nationwide population-based study. Cancer Causes Control 2012;23:273-80.
25. Lai J, Elleray R, Nordin A, et al. Vulval cancer incidence, mortality and survival in England: age-related trends. BJOG 2014;121:728-38.
26. Larsen IK, Småstuen M, Johannesen TB, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer 2009;45:1218-31.
27. Doll R, Payne P, Waterhouse J. Cancer incidence in five continents: a technical report. Berlin: Springer Verlag, 1966.
28. Kim HJ, Fay MP, Feuer EJ, et al. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000;19:335-51.
29. Clegg LX, Hankey BF, Tiwari R, et al. Estimating average annual per cent change in trend analysis. Stat Med 2009;28:3670-82.
30. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11:1048-56.
31. Cancer in Norway 2015. Oslo: Cancer Registry of Norway 2016.
32. Islami F, Ferlay J, Lortet-Tieulent J, et al. International trends in anal cancer incidence rates. Int J Epidemiol 2017;46:dyw276.
33. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 2013;31:4550-9.
34. Arya M, Li R, Pegler K, et al. Long-term trends in incidence, survival and mortality of primary penile cancer in England. Cancer Causes Control 2013;24:2169-76.
35. Stigum H, Samuelsen SO, Traeen B. Analysis of first coitus. Arch Sex Behav 2010;39:907-14.
36. Johnson AM, Mercer CH, Erens B, et al. Sexual behaviour in Britain: partnerships, practices, and HIV risk behaviours. Lancet 2001;358:1835-42.
37. Bajos N, Bozon M, Beltzer N, et al. Changes in sexual behaviours: from secular trends to public health policies. AIDS 2010;24:1185-91.
38. Liu G, Hariri S, Bradley H, et al. Trends and patterns of sexual behaviors among adolescents and adults aged 14 to 59 years, United States. Sex Transm Dis 2015;42:20-6.
39. Hansen BT, Kjaer SK, Arnheim-Dahlstrom L, et al. Trends in age at first intercourse and number of sexual partners among women in Denmark, Norway and Sweden. 31st International Papillomavirus Conference. Cape Town, 2017.
40. Daling JR, Madeleine MM, Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004;101:270-80.
41. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-56.
42. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and sexual behavior: collaborative reanalysis of individual data on 15,461 women with cervical carcinoma and 29,164 women without cervical carcinoma from 21 epidemiological studies. Cancer Epidemiol Biomarkers Prev 2009;18:1060-9.
43. Vink MA, Bogaards JA, van Kemenade FJ, et al. Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data. Am J Epidemiol 2013;178:1161-9.
44. Kim JJ, Burger EA, Sy S, et al. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus. J Natl Cancer Inst 2017;109:1-9.
45. Årsrapport K. Masseundrsøkelsen mot livmorhalskreft (Yearly report of the Norwegian cervical cancer screening program). Oslo, 2015.
46. Kjaer SK, Tran TN, Sparen P, et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis 2007;196:1447-54.
47. Kavanagh K, Pollock KG, Cuschieri K, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis 2017;17:1293-302.
48. Bilet EF, Langseth H, Thoresen SØ, et al. Completeness of invasive cervical cancer at the Cancer Registry of Norway. Acta Oncol 2009;48:1070-3.
49. Miralles-Guri C, Bruni L, Cubilla AL, et al. Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol 2009;62:870-8.
50. van der Avoort IA, Shirango H, Hoevenaars BM, et al. Vulvar squamous cell carcinoma is a multifactorial disease following two separate and independent pathways. Int J Gynecol Pathol 2006;25:22-9.